TGFB1 and neoplasm: Despite not tested on tumor EndMT yet, galunisertib harbors a very safe toxicity profile, with no cardiac toxicity that was a limitation for the use of the first generation of TGF-β inhibitors tested in clinic (Kovacs et al., 2015).